The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 126.00
Bid: 125.00
Ask: 125.20
Change: 2.00 (1.61%)
Spread: 0.20 (0.16%)
Open: 126.00
High: 127.00
Low: 124.00
Prev. Close: 124.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

Thu, 01st Apr 2021 12:00

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

4D Pharma PLC - Leeds-based live biotherapeutic products developer - Posts pretax loss of GBP30.3 million in 2020, widening from GBP29.0 million a year prior. Revenue more-than-doubles to GBP534,000 from GBP211,000. Administrative expenses double to GBP9.1 million from GBP4.4 million. "4D has made significant progress leading the field in the development of live biotherapeutics, and made great strides from a corporate perspective. In addition to the data we have generated in the field of oncology, we completed our merger with Longevity and obtained a NASDAQ listing which, together with a concurrent fundraise, provides 4D with approximately USD40 million of additional capital and a solid financial footing moving forward. This puts 4D pharma in a strong position to capitalise on multiple data readouts from our ongoing trials in asthma and oncology as well as facilitating the move into the clinic with our Parkinson's disease programme," says 4D Pharma.

----------

Sportech PLC - Edinburgh-based gambling technology firm - Posts pretax loss from continuing operations for 2020 of GBP10.6 million, widening 9.3% from GBP9.7 million a year prior. Revenue sinks to GBP20.0 million from GBP33.6 million. "Providing a long-term projection with any degree of certainty in this environment is challenging and unrealistic, however having negotiated several corporate transactions during the last 12 months, when completed, the group will have reduced investors' risk and simplified the structure and the opportunities ahead," says Sportech.

----------

BSF Enterprise PLC - UK-based company formed to undertake an acquisition - Posts pretax loss of GBP93,845 in the year ended September 30, 2020, narrowed from GBP94,398 a year prior. "In the context of this challenging capital raising environment during this Covid-19 pandemic, I believe that BSF represents an extremely attractive proposition to prospective acquisition counterparties considering listing on the London Stock Exchange and I remain confident that we will be able to execute an acquisition that creates value for our shareholders," says BSF.

----------

Nippon Active Value Fund PLC - Japan-focused investment firm - Posts net asset value per share at December 30 of 113.58 pence, in its annual report for the period from incorporation on October 22, 2019 to December 30, 2020. NAV per share increases 14% since IPO. Declares inaugural dividend of 0.85p per share. Says it will not target a dividend for future years but will substantially pay out distributable income for any particular period by way of dividend.

----------

Syncona Ltd - investor in life science companies - Notes results of portfolio company and biotechnology firm Freeline Therapeutics Holdings PLC. Freeline posts pretax loss for 2020 of USD96.2 million, widening from USD53.8 million a year prior. Research & development costs increase to USD76.1 million from USD47.0 million. "We are pleased with our current progress and aim to have three Freeline programs in the clinic by the end of 2021," said Theresa Heggie, Chief Executive Officer of Freeline.

----------

Horizonte Minerals PLC - nickel company focused on Brazil - Posts pretax loss of GBP2.6 million in 2020, widening 13% from GBP2.3 million a year prior. Administrative expenses increase to GBP2.9 million from GBP2.6 million. Says assets are not generating revenues. Does not declare any dividend in 2020, unchanged from a year prior. "The Covid-19 pandemic was unfortunately not an isolated event in 2020, it has continued in to 2021 and we will continue to feel its effects well into the medium term. However, with the accelerating rollout of a number of vaccines we are hopeful for a more certain, less interrupted year in 2021," says Horizonte.

----------

Proteome Sciences PLC - drug development services provider - Posts pretax profit of GBP245,000 in 2020, swinging from a loss of GBP36,000 a year before. Revenue increases to GBP4.8 million from GBP4.7 million. Administrative expenses fall 25% to GBP2.0 million from GBP2.7 million. "We have started an internal analysis on growing our business further in addition to our current activities. We believe that with our specialist expertise the market for our niche services has the potential to grow substantially as proteomics plays an increasingly vital role in drug discovery, development and in the response to current and future medical challenges," says Proteome.

----------

Arbuthnot Banking Group PLC - London-based private and commercial banking - Says subsidiary Arbuthnot Latham completes acquisition of provider of vehicle finance Asset Alliance Group Holdings Ltd. Says the consideration is now anticipated to be approximately GBP10.1 million.

----------

Stanley Gibbons Group PLC - London-based collectible postage stamp retailer - Says it has seen increased levels of digital activity and remote selling of albums and accessories contrasting with lower levels of high ticket sales and in person activities as a result of the third lockdown throughout the year to March 31. Says second half trading was better than the first. "We are hopeful that a vaccine led relaxing of restrictions is not only permanent but encourages activity levels to return at pace, however, this is hard to predict and we have plans in place if this is not how things develop," says Stanley Gibbons.

----------

Great Western Mining Corp PLC - mineral exploration and development company with gold, silver and copper assets in the US - Says drilling has start in Nevada to test a prospective copper target and is likely to be followed by a second hole on the same prospect. "This is an exciting moment for the company, being the first time in its history that it has launched a major drilling campaign for precious metals, while a recent fund-raising will enable us to expand the programme where appropriate," says Chair Brian Hall.

----------

Macfarlane Group PLC - Glasgow-based packaging firm - Announces acquisition of Carters Packaging Ltd in Cornwall. Carters is a distributor of protective packaging in the south-west of England. The acquisition will go for a maximum cash consideration of GBP4.5 million.

----------

1Spatial PLC - Cambridge-based location data software provider - Announces a multiyear contract with Defra to provide a managed service for Rural Payments Agency's Customer Portal and Land Management System. The total potential contract value over five years for 1Spatial is in excess of GBP900,000. The first three years will net the company GBP600,000, or GBP200,000 a year, while Defra has an option to extend for a further two years for GBP300,000.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more
14 Nov 2023 11:29

IN BRIEF: Syncona notes investee company's quarterly loss

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.